FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Early clinical · first deals Has licensed its platform to Lilly and released early clinical data for RZ-001 in liver cancer and glioblastoma.

  • Released interim RZ-001 hepatocellular carcinoma data at AACR 2026. Source
  • Announced an RNA editing therapy licence agreement with Eli Lilly. Source

Roles often seen at this stageResearch & development · Clinical & PV · BD & licensing

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-18

Rznomics

A biotech company developing cancer and genetic-disease therapies on its trans-splicing ribozyme RNA editing and correction platform.

RZ-001

Phase 2

An RNA-based cancer gene therapy in a Phase 1b/2a trial for hepatocellular carcinoma and a Phase 1/2a trial for glioblastoma, with US FDA RMAT designation.

TSR platform (Lilly hearing-loss program)

Technology platform

Its trans-splicing ribozyme platform underpins an RNA editing therapy for hereditary hearing loss with Eli Lilly; Rznomics runs early research.

RZ-003

Stage unconfirmed

An Alzheimer's disease candidate under evaluation with a global pharma company through a material transfer agreement.

Completion reported

Presented interim combination-trial results for RZ-001 in hepatocellular carcinoma orally at AACR 2026.

Completion reported

Signed a global licence agreement with Eli Lilly for an RNA editing therapy for hereditary hearing loss.

Official role guide

Rznomics careers

Current availability unconfirmed

Observed 2026-11-18

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 4

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 알지노믹스, 일라이릴리와 최대 1조9000억원 기술이전 계약 체결 ↗한국경제 · Published 2025-05-15 · Sources checked 2026-11-18 · Original unavailable
  2. 알지노믹스, 바이오USA서 RNA 플랫폼·파이프라인 딜 추진 ↗한국경제 · Published 2026-06-17 · Sources checked 2026-11-18 · Original unavailable
  3. [AACR] 알지노믹스, 'RZ-001' 간세포암 임상 ORR 38.5% 기록 ↗히트뉴스 · Published 2026-04-18 · Sources checked 2026-11-18 · Original unavailable
  4. 플랫폼 기반 기술 수출, 시장의 신뢰 재입증... 알지노믹스 상장 첫날 4배 급등 ↗바이오타임즈 · Published 2025-12-18 · Sources checked 2026-11-18 · Original unavailable